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LETTER TO THE EDITOR
Reply to the letter from Mr Fayers
Sir - I think that Mr Fayers' criticism is extremely harsh.
While I accept that the study was not perfect, it was an
honest attempt to investigate palliative treatment for an
unusual and particularly horrific disease. Because the disease
is rare the number of patients was limited, and in a single-
centre trial there was little that could be done about this. I
accept that Gehan's rule was not used correctly and certainly
accept that the trial was small. Only enough patients were
available to conduct the first stage of Gehan's procedure, for
which 14 patients would be enough to give a 95% probability
of yielding at least one response if the response rate was
20%. Between the two treatments we had 16 patients, for
which the probability of at least one response if the response
was 20% was 97.2%. Equivalently, there was a probability of
95% of finding at least one response if the response rate was
as low as 17%. In fact one (partial) response was obtained
(among the patients receiving cisplatinum).
I would like to draw Mr Fayers' attention to the comments
we made at the end of the paper. Because of the long and
unpredictable survival even in the terminal stages of the
disease, response rates are perhaps a better guide to treat-
ment efficacy than is survival. While I accept his points about
survival it was felt that the categories of response to treat-
ment were more important and were quoted in full. Mr
Fayers seems to feel that we did not dare to quote confidence
intervals. This was an omission and I am grateful to him for
pointing this out. The 95% confidence interval for the mean
survival of the cisplatinum group was 110-765 days and in
the epirubicin group the 95% confidence interval was 0-531
days. Incidentally, a Mann-Whitney test used to compare
the two sets of survival times (all of which were uncensored)
also yield a non-significant difference (P= 0.36).
While I accept the paper is not perfect, Mr Fayers' ext-
remely harsh criticism is unwarranted. The paper attempted
to describe an essentially simple study in an honest fashion
and found no difference in response rates for two commonly
used regimens. Obviously the Editor and reviewers recog-
nised the paper for what it was and that is why it was
published in the journal.
Yours etc,
A.S. Jones
Royal Liverpool University Hospital,
Prescot St, PO Box 147,
Liverpool L69 3BX, UK.
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